АРТЕРИАЛДЫ ГИПЕРТОНИЯСЫ БАР ПАЦИЕНТТЕРДІ ЕМДЕУ ҮШІН ЛИЗИНОПРИЛ МЕН АМЛОДИПИННІҢ ОҢТАЙЛЫ БІРІКТІРІЛУІ
##semicolon##
https://doi.org/10.31082/1728-452X-2020-211-212-1-2-31-39##semicolon##
артериялық гипертензия##common.commaListSeparator## лизиноприл##common.commaListSeparator## амлодипин##common.commaListSeparator## ВиваКор##article.abstract##
Arterial hypertension (AH) remains one of the most common diseases in the world. Reducing cardiovascular risk of mortality from cardiovascular complications is a priority in the treatment of hypertension. Targets of hypertension therapy is to achieve SBP/DBP <140/80 mm Hg. article, regardless of cardiovascular risk and comorbidity. The choice of antihypertensive therapy depends on blood pressure levels, the presence or absence of concomitant diseases, lesion of target organs. Effective and long-lasting control of AH proved by the use of combinations of antihypertensive drugs, including antagonists and ACE inhibitors.
The purpose of the study. Evaluation of clinical efficacy and safety of fixed combination antihypertensive therapy using lisinopril combined with amlodipine in patients with hypertension.
Material and methods. The study included 30 respondents from essential hypertension II-III degree (ESH/ESC, 2018) aged 35 to 75 years. Patients were treated with the schema a (lisinopril 10 mg, amlodipine 5 mg) and scheme b (lisinopril 20 mg, amlodipine 10 mg) fixed combination therapy with the drug VivaCor® once in the morning. The period of observation was 3 months. At the time of inclusion and at the end of the study all respondents was performed echocardiography, daily monitoring of blood pressure, evaluation of laboratory and instrumental methods of research.
Results and discussion. The combination of lisinopril with amlodipine has a fairly high antihypertensive activity, provides a significant cardioprotective effect and is an integral part of antihypertensive therapy in the long-term strategy of administering patients with high hypertensive / very high total cardiovascular risk.
Conclusions:
1. The use of a fixed combination of lisinopril and amlodipine in patients with hypertension instead of free or other two-component combinations leads to its target level within 3 months of therapy.
2. Taking a fixed combination of lisinopril and amlodipine is effective and safe.
3. Therapy using the combined drug VivaCor® in patients with high / very high risk of hypertension prevents further pathological remodeling of the heart.
4. The combination of amlodipine and lisinopril is metabolically neutral and well tolerated by patients.
##submission.citations##
Kobalava J D, Conradi AO, Nedogoda SV, Shlyakhto EV. Arterial hypertension in adults. Clinical recommendations. 2020; p. 13
Zaim J, Amira S, Sevala H, Aziz S, Edhem R, Amina V. Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness. Med Arch. 2019 Jun;73(3):157–162. PMCID: PMC6657010. PMID: 31391706. DOI: 10.5455 / medarh.2019.73.157-162
Kyle J, Suzanne O, Barry R. D, Larisa G. T, Prevention of Heart Failure in Hypertension - Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. J Am Heart Assoc. 2019 Apr 16;8(8):e011961. PMCID: PMC6507192. PMID: 30943832. DOI: 10.1161 / JAHA.119.011961
Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217–223. https://doi.org/10.1016/S0140-6736(05)70151-3
Berkinbaev SF, Junusbekova GA, Abdikaliev NA, Musagalieva AT, Koshumbaeva KM, Isabekova AKh, Akhyt BA, Akpanova DM, Usaeva GR. The prevalence of risk factors for major cardiovascular diseases (according to an epidemiological study in Almaty and the Almaty region). Meditsine (Almaty) = Medicine (Almaty). 2016;9(171):14-18. (In Russ.)
Williams B, Mancia G, Spiering W, et al. 2018 ESC / ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041. PMID: 30234752. DOI: 10.1097 / HJH.0000000000001940
Chazova IE, Zhernakova YuV. [on behalf of experts]. Clinical recommendations. Diagnosis and treatment of arterial hypertension. Systemic hypertension. 2019;16(1):6–31. DOI: 10.26442 / 2075082X.2019.1.190179
Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. European Heart Journal. October 2011;32(20):2499–2506. https://doi.org/10.1093/eurheartj/ehr177
Gupta AK, Arshad S, Poulter NR. Antihypertensive Agents, Compliance Compliance, Safety, and Effectiveness of Fixed – Dose Combinations of Antihypertensive Agents. A Meta – Analysis Hypertension. 2010;55:399-407. PMID: 20026768. DOI: 10.1161 / HYPERTENSIONAHA.109.139816
Katelnitskaya LI, Khaisheva LA. From short-acting nifedipine to amlodipine and fixed combinations. The problem is in the light of current recommendations for the treatment of hypertension. Ratsionalnaia farmakoterapiia v kardiologii. 2008;2:76–80. (In Russ.). https://doi.org/10.20996/1819-6446-2008-4-2-76-80
Podzolkov VI, Bragana AE, Osadchy KK, Fixed combination of lisinopril + amlodipine + rosuvastatin: prospects for use in patients with arterial hypertension and concomitant dyslipidemia. Terapevticheksii arkhiv = Therapeutic Archive. 2017;12:134. (In Russ.). PMID: 29411773. DOI: 10.17116/terarkh20178912133-140
Gridina SA, Povetkin SV, Comparative Assessment of Effects of Free and Fixed Combinations of Hypotensive Drugs on Quality of Life of Patients With Arterial Hypertension of High and Very High Risk. Kardiologiia = Cardiology. 2016 Mar;56(3):25-29. (In Russ.). PMID: 28294885. DOI: 10.18565/cardio.2016.3.25-29
Semenova AE, Sergienko IV. Lisinopril, amlodipine, rosuvastatin - a new fixed combination in the fight against cardiovascular diseases. Kardiologiia = Cardiology. 2017;57(10): 73–79. (In Russ.). DOI: 10.18087 / cardio.2017.10.10044
Yousefpour A, Modarress H, Goharpey F, Amjad-Iranagh S. Combination of anti-hypertensive drugs: a molecular dynamics simulation study. J Mol Model. 2017 May;23(5):58. DOI: 10.1007 / s00894-017-3333-9. Epub 2017 Apr 10. PMID: 28397088
Ostroumova OD, Kochetkov AI, Kopchenov II, Fomina VM. Arterial hypertension in combination with overweight and obesity. Possibilities of a combination of amlodipine and lisinopril. Part 2. Antihypertensive and organoprotective effects of a fixed combination of amlodipine / lisinopril in patients with arterial hypertension in combination with overweight and obesity. Ratsionalnaia farmakoterapiia v kardiologii = Rational Pharmacotherapy in Cardiology. 2017;13(6):841-850. (In Russ.) DOI: 10.20996 / 1819-6446-2017-13-6-841-850
Arslanagic A, Bajraktarevic A. The effect of lisinopril and amlodipine treatment on left ventricular hypertrophy in hypertensive patients. Med Arh (Bosnia and Hercegovina). 2006;60(6 Suppl. 2):71–73. PMID: 18172987. [Indexed for MEDLINE]
Cappuccio FP, Markandu ND, Singer DR, MacGregor GA. Amlodipine and lisinopril in combination for the treatment of essential hypertension: efficacy and predictors of response.
J Hypertens. 1993 Aug;11(8):839–847. PMID: 8228208. DOI: 10.1097/00004872-199308000-00011
Naidu MU, Usha PR, Rao TR, Shobha JC. Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension. Postgrad Med J. 2000 Jun;76(896):350–353. PMID: 10824049 PMC1741615. DOI: 10.1136 / pmj.76.896.350
Rogoza AN, Agaltsov MV, Sergeeva MV. Daily monitoring of blood pressure: options for medical opinions and comments. - Nizhny Novgorod: DECOM, 2005. 64 p.
Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289(18):2363-2369. PMID: 12746359. DOI: 10.1001/jama.289.18.2363
Napalkov DA, Sokolova AA. Features of management of patients with arterial hypertension in combination with coronary heart disease: modern approaches. Ratsionalnaia farmakoterapiia v kardiologii = Rational Pharmacotherapy in Cardiology. 2017;13(6):851-855. (In Russ.). DOI: 10.20996/1819-6446-2017-13-6-851-855
